George A. Rozanski, PhD

George Rozanski is an expert on the competitive effects of mergers and acquisitions and the analysis of alleged anticompetitive conduct, including vertical restraints, IP licensing practices, and price-fixing. He has substantial experience in developing and applying theories of competitive effects and in using economic models and empirical techniques to assess and quantify predicted effects of proposed mergers, agreements, and single-firm conduct.

Dr. Rozanski has more than 25 years of experience in antitrust analysis. Prior to joining Bates White, he served as Chief of the Economic Regulatory Section of the Antitrust Division of the US Department of Justice. In that role, Dr. Rozanski analyzed proposed mergers and acquisitions, single-firm conduct, and proposed changes in economic regulations and legislation that could affect competition and market outcomes. He had responsibility for conducting, supervising, and presenting the agency’s economic analysis in numerous investigations and litigations involving a wide variety of industries, including telecommunications, banking and financial services, intermediate capital goods, differentiated consumer products, Internet music and video distribution services, financial trading platforms, pharmaceuticals, medical devices, steel, defense, and homogeneous manufactured goods.

In addition to his extensive experience in all aspects of the analysis of horizontal mergers, Dr. Rozanski has significant experience and expertise in the antitrust analysis of vertical restraints, vertical mergers, and allegations of price-fixing. Lexology Index named Dr. Rozanski as the 2020 Client Choice winner for competition economists in the United States, the first year the award was given to economists. Dr. Rozanski has also been named on the Lexology Index (formerly Who’s Who Legal) list of leading competition economists since 2010 and a Thought Leader in Competition since 2020.

• Provided economic analysis to NFP Corp. in its $13 billion sale to Aon and assisted with submissions to DOJ. The matter concluded without a Second Request and was consummated in April 2024.
• On behalf of insurance broker Willis Towers Watson during its proposed $30 billion merger with Aon, assisted at all stages of merger review. 
• Working on behalf of a pharmaceutical benefits manager in connection with the Federal Trade Commission's 6(b) study.
• In a matter related to allegations of price-fixing for generic drugs, analyzing issues of liability and damages on behalf of a pharmaceutical manufacturer.
• On behalf of Thermo Fisher Scientific Inc., assisted with reviews by antitrust authorities in multiple jurisdictions of its offer to acquire Qiagen N.V.
• On behalf of the merging parties, retained to identify competitive overlaps and analyze likely competitive effects of a proposed transaction in the beverage industry. Analysis included retrospective merger analysis and empirical analysis of other natural experiments. Presentations and white papers submitted to Federal Trade Commission.
• Retained as consulting expert on behalf of two merging newspaper publishers to analyze both advertising and subscription aspects of the newspaper business in regard to concerns by the Department of Justice (DOJ) about the competitive effects of the merger. The DOJ let the 30-day waiting period expire, thus clearing the transaction.
• On behalf of Express Scripts, analyzed possible concerns related to horizontal effects of its proposed merger with Cigna in markets for PBM services and Medicare Part D insurance.
• On behalf of DuPont, analyzed likely competitive effects of its proposed merger with Dow Chemical in a wide range of markets, including seeds and transgenic traits, agricultural chemicals, and specialty polymers.
• On behalf of Express Scripts, provided analysis for its acquisition of MyMatrixx and, previously, its acquisition of Medco.
• On behalf of parties seeking to combine their purchasing of generic pharmaceuticals, co-led a team in performing detailed economic analysis to assess whether the expanded Group Purchasing Organization would have anticompetitive buyer market power, also referred to as monopsony power.
• On behalf of CEMEX, S.A.B. de C.V. (“CEMEX”) and Grupo Cementos de Chihuahua, S.A.B. de C.V. (“GCC”), conducted analysis presented to the Federal Trade Commission in support of a transfer of manufacturing and distribution assets for cement from CEMEX to GCC.

• Working on behalf of merging hospitals, identified competitive overlaps, assessed relevant markets, and analyzed likely competitive effects.

• On behalf of Holcim Ltd. and Lafarge SA, which proposed a $25 billion merger that would create the world’s largest cement manufacturer, analyzed potential competitive effects in both the United States and Canada for aggregates, ready-mix concrete, and cement.

• Worked on behalf of Dr. Oetker to analyze the competitive effects of its proposed acquisition of McCain Foods’ North American frozen pizza business.
• On behalf of Thermo Fisher Scientific, advised on the likely competitive effects of its proposed $13.6 billion acquisition of Life Technologies, firms that provide analytical and laboratory services and products.
  
• Conducted detailed economic analysis on behalf of Eli Lilly in connection with its $5.4 billion acquisition of Novartis Animal Health.
• Provided support for expert testimony on behalf of American Express in its litigation with DOJ and on subsequent related matters.
• Provided liability and damages analysis for Dupont in its litigation against Monsanto regarding alleged antitrust and intellectual property violations.
  
• Provided support for expert testimony on damages on behalf of American Airlines, which alleged anticompetitive conduct by Sabre in markets for airline ticket booking services.
  
• On behalf of Constellation Brands, analyzed the competitive effects of Anheuser-Busch InBev and Grupo Modelo’s proposed divestiture of brewery and distribution assets to Constellation in response to DOJ's concerns about their proposed merger.
• Provided analysis on behalf of Grifols in connection with its acquisition of Talecris, both companies involved in the manufacture and sale of plasma-derived therapies used to treat a range of medical conditions.
  
• In Omnicare v. United Health, served as a testifying expert for United Health to assess damages in a lawsuit alleging that premerger coordination led to the joint exercise of monopsony power.
• Provided analysis to Delta Air Lines and Northwest Airlines in connection with their proposed merger which was under investigation by DOJ.